strong top bottom line guidanc estim
ep estim consensu newli
issu ep guidanc set rais estim
price target estim ep vs
prior target multipl reflect increas earn improv visibl
sale forecast consensu sale
estim livestock sale
forecast companion sale
estim sale
estim ou livestock sale estim
ou companion sale forecast total
revenu guidanc set last publish revenu
estim review reiter expect livestock
growth ou companion anim also expect post solid gain
albeit rate given larger base
gpm ahead estim sg
forecast line forecast net expens
estim tax rate
estim ad ep share count line estim
guidanc cost sale revenu approxim sg
 net expens approxim
tax rate previous issu cog expens line last
publish estim sg spend bit higher reflect stronger top-lin
dermatolog portfolio apoquel cytopoint sale
estim updat guidanc dermatolog call sale reach
vs prior guidanc next year last publish apoquel
cytopoint sale estim simparica oral flea tick sale
estim season weak quarter pharmaq aquacultur sale
estim
pleas see page report import disclosur
signific growth opportun stabl visibl anim health market
driven global demand safe protein boost new companion anim drug
zoeti well suit benefit given market-lead posit segment recent
launch product apoquel cytopoint simparica fish vaccin strong potenti
pipelin acquisit enhanc revenu outlook oper restructur
streamlin product geograph focu improv profit
effici initi plan next year
apoquel cytopoint sale trend
sale compound-annual-growth-rate
ep compound-annual-growth-rate
apoquel cytopoint simparica uptak
apoquel cytopoint simparica sale
greater expect
signific product emerg
new oper restructur
restructur provid greater
influx small new competitor dampen
zoeti inc engag discoveri develop manufactur commerci
anim health medicin vaccin focu livestock companion anim
primari livestock speci cattl beef dairi swine poultri sheep fish
primari companion anim speci dog cat hors zoeti spun
cowen compani
chg total good profit margin intang oper incom expens incom inc/loss non-control share cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk price includ abil re-suppli apoquel success pipelin
product weather/diseas risk busi success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock zoeti secur
cowen compani llc act co-financi advisor nexvet biopharma public limit comapni connect acquisit zoeti inc announc april
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
